CENTREXION THERAPEUTICS overview

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a biotechnology company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs and in-licensing undervalued mid-stage drug candidates across multiple target therapeutic areas, today announced that it has raised $40.5 million of cash via: Convertible security investments from Lilly and Exome Asset Management – each a new investor in Centrexion; Collaboration-related investment from...

BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today announced that the U.S. Patent and Trademark Office has issued a composition of matter patent (Patent No. 10,493,047) entitled “Stable Aqueous Capsaicin Injectable Formulations and Medical Uses Thereof,” which provides coverage for the formulation of capsaicin used in the company’s CNTX-4975 product...

BOSTON, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today announced it will present posters on CNTX-4975 at the 2019 American College of Rheumatology (ACR) Annual Meeting Conference taking place November 8-13, 2019 in Atlanta, Georgia and at the 2019 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly taking place November 14-17, 2019 in...

- CNTX-4975 Phase 3 clinical development program fully enrolled - - VICTORY-1 pivotal and VICTORY-3 open-label topline results expected in Q1 2020; VICTORY-2 pivotal results expected in Q3 2020 - BOSTON, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today announced completion of patient enrollment in its third Phase 3 trial, VICTORY-3. VICTORY-3 is a randomized,...

BOSTON, Sept. 04, 2019 (GLOBE NEWSWIRE) -- In a release issued earlier today by Centrexion Therapeutics Corporation (NASDAQ: CNTX), please note that the headline should read "Centrexion Therapeutics Announces CNTX-4975, CNTX-6970 and CNTX-6016 Data Presentations at PAINWeek 2019 National Conference," as opposed to "Centrexion Therapeutics Announces CNTX-4975, CNTX-0290 and CNTX-6970 Data Presentations at PAINWeek 2019 National Conference." The corrected release follows: Centrexion Therapeutics...

BOSTON, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today announced it will present one oral presentation on CNTX-6970 and four poster presentations on CNTX-4975, CNTX-6970 and CNTX-6016 at the 13th Annual PAINWeek National Conference taking place in Las Vegas, Nevada from September 3-7, 2019. Full abstracts are available online at the PAINWeek Abstract Book. The...

-- Administration procedure designed to optimize physician and patient experience and convenience -- -- Company also shares interim analysis of 719 patients in VICTORY-3 Phase 3 open-label trial indicating the studied streamlined administration procedures maintain patient comfort -- -- Data to be presented at the 2019 Florida Society of Interventional Pain Physicians Conference -- BOSTON, July 18, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing...

BOSTON, June 11, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation , a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today announced that it will report data from two clinical studies of CNTX-4975, including an assessment of the company’s proprietary cooling method for reducing procedural pain, at the 2019 European League Against Rheumatism (EULAR) Annual Conference taking place June 12-15, 2019 in Madrid, Spain. “We are...